Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | KIF18A | Q8NI77 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3287681 | 0.85 | PDE10A (0.46) | GRM4PDE10AMAP3K12MAPK1PIK3CA | |
| SCHEMBL3288576 | 0.73 | PDE10A (0.45) | GRM4PDE10AMAP3K12HTR2A | |
| SCHEMBL23344776 | 0.72 | MTOR (0.44) | PIK3CA | |
| SCHEMBL23344762 | 0.69 | LRRK2 (0.39) | LRRK2PIK3CA | |
| SCHEMBL23344681 | 0.68 | FFAR2 (0.40) | MAP3K12KIF18ALRRK2IDH1 | |
| SCHEMBL14436539 | 0.67 | CYP1A2 (0.45) | — | |
| SCHEMBL23344656 | 0.67 | AR (0.42) | MAPK1SYK | |
| SCHEMBL23344783 | 0.66 | CYP1A2 (0.48) | — | |
| SCHEMBL30267157 | 0.65 | CHRNB2 (0.55) | MAP3K12SYKPIK3R1PIK3CA | |
| SCHEMBL23107400 | 0.64 | CHRNB2 (0.55) | MAP3K12PIK3R1PIK3CAIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | GRM4 668/4885PDE10A 965/4885KCNQ3 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.